Javascript must be enabled to continue!
Lympedema Therapies
View through CrossRef
Secondary lymphedema refers to a condition in which the affected extremity develops progressive hypertrophy due to lymphatic fluid retention. Worldwide, secondary lymphedema is most often associated with parasitic infection; within the United States, secondary lymphedema is most often caused by surgical disruption of the lymphatic drainage basins due to cancer surgery and/or radiation. For patients with lymphedema secondary to parasitic infection, treatment of the offending infectious organism (Wuchereria bancroftii) is critical. For patients with surgical disruption of the lymphatic drainage basin(s), patients are first managed non-operatively with compression and manual lymphatic drainage massage. Over the past decade, surgical techniques have been developed and implemented to improve lymphatic drainage for patients with post-surgical secondary lymphedema. These procedures, including lymphovenous bypass or vascularized lymph node transfer, are aimed at reconstituting lymphatic drainage and reducing lymphatic retention to alleviate early lymphedema. An appreciation of the underlying physiology responsible for secondary lymphedema, and diagnosis and management is required to provide timely and appropriate care for these patients.
This review contains 2 tables, 4 figures, and 32 references
Keywords: lymphedema, lymphedema treatment, secondary lymphedema, complete decongestive therapy, lymphovenous bypass, vascularized lymph node transplantation, debulking surgery, ICG lymphangiography, lymphedema staging
Title: Lympedema Therapies
Description:
Secondary lymphedema refers to a condition in which the affected extremity develops progressive hypertrophy due to lymphatic fluid retention.
Worldwide, secondary lymphedema is most often associated with parasitic infection; within the United States, secondary lymphedema is most often caused by surgical disruption of the lymphatic drainage basins due to cancer surgery and/or radiation.
For patients with lymphedema secondary to parasitic infection, treatment of the offending infectious organism (Wuchereria bancroftii) is critical.
For patients with surgical disruption of the lymphatic drainage basin(s), patients are first managed non-operatively with compression and manual lymphatic drainage massage.
Over the past decade, surgical techniques have been developed and implemented to improve lymphatic drainage for patients with post-surgical secondary lymphedema.
These procedures, including lymphovenous bypass or vascularized lymph node transfer, are aimed at reconstituting lymphatic drainage and reducing lymphatic retention to alleviate early lymphedema.
An appreciation of the underlying physiology responsible for secondary lymphedema, and diagnosis and management is required to provide timely and appropriate care for these patients.
This review contains 2 tables, 4 figures, and 32 references
Keywords: lymphedema, lymphedema treatment, secondary lymphedema, complete decongestive therapy, lymphovenous bypass, vascularized lymph node transplantation, debulking surgery, ICG lymphangiography, lymphedema staging.
Related Results
Complementary therapies
Complementary therapies
Complementary therapies are popular with people who have cancer. They are used in addition to, and to complement, conventional therapies for cancer. They can be grouped together wi...
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
Alternative therapies, 1990: An overview
Alternative therapies, 1990: An overview
AbstractThe availability of alternative therapies for many health problems is a well‐documented historical fact. Alternative therapies are generally understood to be those therapie...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies
Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies
Abstract
Background: Better understanding of the disease biology has led to significant advances in the treatment of CLL. Oral targeted agents such as ibrutinib and ...
Daratumumab, Carfilzomib, Pomalidomide and Elotuzumab for the Treatment of POEMS Syndrome- The Mayo Clinic Experience
Daratumumab, Carfilzomib, Pomalidomide and Elotuzumab for the Treatment of POEMS Syndrome- The Mayo Clinic Experience
Abstract
POEMS syndrome is a rare paraneoplastic syndrome and therapies are directed against plasma cells that produce the proteins that cause this syndrome. Novel therapie...
Current therapeutic trends for tinnitus cure and control – a scoping review
Current therapeutic trends for tinnitus cure and control – a scoping review
AbstractIntroductionChronic tinnitus treatment has been an enigma due to a lack of practice insights. To date, there has been limited evidence-based research on tinnitus therapies ...
Abstract 1791: An injectable depot technology for sustained locoregional delivery improves the efficacy and safety of immunotherapies and adoptive cell therapies
Abstract 1791: An injectable depot technology for sustained locoregional delivery improves the efficacy and safety of immunotherapies and adoptive cell therapies
Abstract
Advances in immunotherapy have revolutionized care for cancer patients. Unfortunately, many approaches fail to mount a robust anti-cancer effect, in part du...

